GlassScriptPhysician profile
Joshua Rosenbloom
NPI 1871856310
$16,730.24
in general payments reported to CMS, 2019-2025
44 companies · $2,412 in 2025
The $2,412 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,302 · 2020: $2,144 · 2021: $2,245 · 2022: $2,317 · 2023: $2,391 · 2024: $2,920 · 2025: $2,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,529 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,529.36 |
| Education | $193.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,782.65 | 2019-2025 | Linzess, Viberzi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,722.50 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,269.50 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $1,142.82 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $1,054.55 | 2019-2024 | Sucraid, Sucraid |
| Celgene Corporation | $703.25 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $577.92 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $564.12 | 2023-2025 | |
| Pfizer INC. | $489.37 | 2019-2025 | |
| Redhill Biopharma INC. | $359.43 | 2020-2022 | |
| Gilead Sciences, INC. | $350.46 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $342.53 | 2019-2025 | Ocaliva |
| Daiichi Sankyo INC. | $340.51 | 2019-2022 | |
| Amgen INC. | $324.49 | 2020-2023 | Avsola, Amjevita |
| Regeneron Healthcare Solutions, INC. | $291.87 | 2023-2025 | Dupixent |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Rosenbloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.